Follow us on :


Trends in Cancer Research and Chemotherapy

Online ISSN: 2517-7206

Dr. Vita Golubovskaya (Editor-in-Chief)

University of Buffalo, SUNY, Buffalo, NY

Trends in Cancer Research and Chemotherapy is a peer-reviewed online open access journal seeking to publish all types of articles on all aspects of cancer research and chemotherapy, including the pathophysiology, prevention, diagnosis and treatment of cancers. TCRC welcomes submissions also concerning molecular and cellular biology, genes, epidemiology, and clinical trials which are directly or indirectly related to cancer and chemotherapy.

Trends in Cancer Research and Chemotherapy show window of the progress of oncological sciences around the globe and presents research with the objective to serve as the ideal source to educate physicians, dentists, nurses, students, social workers as well as other allied health professionals, patients, and the public to improve current cancer education techniques and solve current problems.

International in scope, the journal features a varied editorial board made up of professors all over the world working in the field, who see the importance of disseminating information about improving cancer education worldwide. The readership has expanded beyond the boundaries of the country.

Trends in Cancer Research and Chemotherapy welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, opinion, commentary, letter to the editor, technical report, illustrations etc and follows open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.

Trends in Cancer Research and Chemotherapy welcomes direct submissions from authors: Attach your word file with an e-mail and send it to: submissions@oatext.com alternatively to: editor.tcrc@oatext.com

Please, follow the Instructions for Authors. In the cover letter add the name and e-mail address of 5 proposed reviewers (we can choose them or not).

Copyright is retained by the authors and articles can be freely used and distributed by others. Articles are distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published by Trends in Cancer Research and Chemotherapy, is properly cited.

Dr. Vita Golubovskaya


Dr. Vita Golubovskaya is a Director of Research and Business Development at Promab Biotechnologies leading research of novel anti-cancer immunotherapies including CAR-T cell therapy. She has more than 20 years of experience in cancer research, oncology and immunology.

Previously, Dr. Golubovskaya was a Research Associate Professor at Roswell Park Cancer Institute and Research Professor at University of Buffalo, SUNY, Buffalo, NY. She holds Ph.D in Cell Biology from Institute of Cytology, St. Petersburg, Russia. Dr. Golubovskaya authored more than 80 publications, 20 patents and several book chapters.

She was awarded Susan Komen Grant for Breast Cancer studies as a Principal Investigator, NCI NIH grants as a Co-Investigator and STTR grant as a PI. Dr. Golubovskaya served as a Guest Editor in Frontiers in Bioscience, Anti-Cancer Agents in Medicinal Chemistry and Cancers. She is an Active Member of AACR.

Executive Editor


Mohammed Rachidi

Director of Research
Molecular Genetics of Human Diseases
French Polynesia
University Paris Denis Diderot
Paris
France

Editorial Board


Soldano Ferrone

Department of Surgery
Massachusetts General Hospital
Harvard Medical School
USA

Synho Do

Assistant Professor
Department of Radiology
Massachusetts General Hospital
Harvard Medical School
USA

Kazushi Inoue

Associate Professor
Department of Pathology (Tumor Biology)
Wake Forest University School of Medicine
USA


Mohammad O. Hoque

Associate Professor
Department of Otolaryngology-Head & Neck Surgery, Urology and Oncology
Johns Hopkins University School of Medicine
USA

Yumay Chen

Associate Professor
Department of Medicine
University of California
USA

Łukasz Piątek

Institute of Biomedical Engineering and Computer Science
Technical university Ilmenau
Germany


Alireza Heidari

Full Professor and Academic Tenure of Chemistry & Director of the BioSpectroscopy Core Research
USA

Junya Sato

Department of pharmacy
Shizuoka Cancer Center
Japan

Sabry M. Attia

Professor of Pharmacology and Toxicology
College of Pharmacy, King Saud University
Saudi Arabia


Yongqiang Chen, Ph.D

Research Institute in Oncology and Hematology
CancerCare Manitoba
Canada

Patrizia Straccia

Cytologist
Department of surgical pathology
Catholic University of Sacred Hearth, Rome Italy

Ewa Lucja Gregoraszczuk

Full proffesor at Jagiellonian University
department of physiology
Poland


Shakeel Ahmed

Assistant Professor
Government Degree College Mendhar
University of Jammu
India

Muhammad Ovais

Doctoral Research Scholar at CAS Key Lab
University of Chinese Academy of Sciences
china

Massimo Gentile

Associate Professor of Hematology
University of Rome
italy


Rabbab Oun

Department of Physical chemistry
Kaplan Glasgow University
UK.

Mohamad Hafizi Abu Bakar

Department of Bioprocess Technology
Universiti Sains Malaysia
malysia

Chung-Yi Chen

School of Medical and Health Sciences
Dean and Professor
Fooyin University
Taiwan


Vaishali Kapoor

Department of Radiation Oncology
Postdoctoral Research Associate
Washington University School of Medicine
USA

GIULIO TARRO

Department of Cancer Research
Professor and President
Foundation T. & L. de Beaumont Bonelli for cancer research
Italy

Rammurti T. Kamble

Center for Gene Therapy
Professor
Baylor College of Medicine
USA


Andrei Braester

Institute of Hematology
Galilee Medical Center
Israel

Guy-Armel Bounda

Clinical Pharmacy Department
School of Basic Medicine and Clinical Pharmacy
China Pharmaceutical University
china

Archontia Mahairidou

Consultant Anesthetist Intensive Care Unit
Komotini General Hospital Rodopi
Greece


Ewa L Gregoraszczuk

Professor of Endocrinology
Head of Department Physiology and Toxicology of Reproduction
Jagiellonian University in Krakow, POLAND

Arshad Islam

Department of Physiology and Biophysics
Institute of Biological Sciences
Universidade Federal de Minas Gerais
Brazil

Michael Chiemeli Asuzu

Professor of Public Health & Community Medicine College of Medicine
University of Ibadan
Nigeria


Thomas Naves

Department of Medicine
University of Limoges
France

Thiagarajan Venkatesan

Associate Research Scientist
Rumbaugh Goodwin Institute for Cancer Research Nova Southeastern University
South University Drive
USA

In Press

Volume 1, Issue 3


CDK 4/6 Inhibitors in Hormone Receptor-Positive Advanced Breast Cancer: A Meta-analysis

Ezzeldin M. Ibrahim Wesal M. Eldahna Omalkhair A. Abulkhair Mubarak M. Al-Mansour Meteb O. Al-Foheidi

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

September 24, 2018


Current Issue

Volume 1, Issue 2


Radiation necrosis after definitive chemo-radiation of anal canal squamous cell carcinoma

Tangel Chang Joseph Trunzo Aryavarta Kumar

Case Report -Trends in Cancer Research and Chemotherapy(TCRC)

June 21, 2018


Novel biotechnological opportunities in thyroid cancer metastasis based on LIMD2 differential expression

Rodrigo Pinheiro Araldi Janete Maria Cerutti

Review Article-Trends in Cancer Research and Chemotherapy(TCRC)

July 18, 2018


Clinical prolonged follow up of patients with advanced cancers after chemotherapy with traditional medicine (78 cases)

George Zhu

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 14, 2018


miRNA in oncogenesis

Mansi Verma Susinjan Bhattacharya

Review Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 24, 2018


Attitudes and Current Practices of Primary Care Clinicians in Performing Anal Cancer Screening

Kelly Scarberry Bona Ko Jay J Idrees Justin T Brady Emily Steinhagen Sharon L Stein

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 27, 2018


Immunoscintigraphy with 99mTc-14F7 and 99mTc-Nimotuzumab in patients with non-small cell lung cancer

Yamile Pena Tania Crombet Alex Vergara Juan F. Batista Leonel A. Torres Anais Prats

Image Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 28, 2018


Archive


Volume 1
C

Radiation necrosis after definitive chemo-radiation of anal canal squamous cell carcinoma

Tangel Chang Joseph Trunzo Aryavarta Kumar

Case Report -Trends in Cancer Research and Chemotherapy(TCRC)

June 21, 2018


Novel biotechnological opportunities in thyroid cancer metastasis based on LIMD2 differential expression

Rodrigo Pinheiro Araldi Janete Maria Cerutti

Review Article-Trends in Cancer Research and Chemotherapy(TCRC)

July 18, 2018


Clinical prolonged follow up of patients with advanced cancers after chemotherapy with traditional medicine (78 cases)

George Zhu

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 14, 2018


miRNA in oncogenesis

Mansi Verma Susinjan Bhattacharya

Review Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 24, 2018


Attitudes and Current Practices of Primary Care Clinicians in Performing Anal Cancer Screening

Kelly Scarberry Bona Ko Jay J Idrees Justin T Brady Emily Steinhagen Sharon L Stein

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 27, 2018


Immunoscintigraphy with 99mTc-14F7 and 99mTc-Nimotuzumab in patients with non-small cell lung cancer

Yamile Pena Tania Crombet Alex Vergara Juan F. Batista Leonel A. Torres Anais Prats

Image Article-Trends in Cancer Research and Chemotherapy(TCRC)

August 28, 2018


Novel CAR-T cells to eliminate cancer

Vita Golubovskaya Lijun Wu

Editorial-Trends in Cancer Research and Chemotherapy(TCRC)

May 07, 2018


Fast onset of relief after topical phenytoin in neuropathic pain after chemotherapy

Jan M. Keppel Hesselink David J. Kopsky

Case Report-Trends in Cancer Research and Chemotherapy(TCRC)

May 16, 2018


Synthesis and antimicrobial activity of imidazolium salts

Kasim Ocakoglu Huseyin Tasli Mine Hosgor-Limoncu Fatma Yurt Lambrecht

Research Article-Trends in Cancer Research and Chemotherapy(TCRC)

May 18, 2018


How will a GABA deficiency in endocrine pancreas transform stem cells into tumor cells?

Maurice Israel

Letter to Editor -Trends in Cancer Research and Chemotherapy(TCRC)

May 25, 2018


Typical facial appearence of chronic GVHD

H.Gozde GUL M.Ali ERKURT Irfan KUKU Emin KAYA

Image -Trends in Cancer Research and Chemotherapy(TCRC)

May 30, 2018


Submit Manuscript


Trends in Cancer Research and Chemotherapy welcomes direct submissions from authors: Attach your word file with an e-mail and send it to: submissions@oatext.com alternatively to: editor.tcrc@oatext.com

Publication Charges


Trends in Cancer Research and Chemotherapy is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.

The publication charges for Trends in Cancer Research and Chemotherapy are GBP 1460.

Frequently Asked Questions (FAQs)

Why are your charges set at these levels?

All articles published in OA Text are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.

Our financial goals are to:

  • Recover capitalization costs;
  • Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
  • Bend the publication-charge cost downward over time.

Who will pay the APC?

Corresponding author or Co-authors has to make the payment on acceptance of the article.

When should I pay?

Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.

*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.

How do I pay?

Authors or institutions can make payments by two modes as per their convenience.

  1. Wire/Bank transfer
  2. Card payment

Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.

Can I be eligible for wavier on APC?

The waiver request will be considered on a case-by-case basis, and will be provided accordingly.

*The Waiver requests must be made during the submission process and will not be accepted after  processing of the manuscript.

Do I have to pay if my manuscript is rejected?

No, Article processing charges will not be applicable for articles rejected by the Editorial office.

Withdrawal Charges

Are reprints of my article included in the article processing charges (APCs)?

No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.